Type 2 Diabetes

More research and education could to prevent inherent risks

Five new and upcoming medical devices will help your patients manage their diabetes care.

Larry Altstiel, MD, PhD, EVP, Chief Medical Officer, vTv Therapeutics also discussed their team’s programs in type 2 diabetes. One is an activator of an enzyme called glucocynase – a master regulator for glucose in the body. According to Altstiel, when glucose is too high, it either shuns it off to energy production or stores it in the form of glycogen. It’s an insulin independent way of how the body controls glucose.

Vascular death was 2.5 times more common with 0.3 mg ranibizumab than with sham.

April news highlights the importance of timely eye examinations in young patients with diabetes and the efficacy of a teleretinal screening program.

Praluent can help patients with clinical ASCVD or HeFH

Our April list includes predictors of fracture risk, endocrine-disrupting chemicals, and CV effects of thyroid dysfunction.

This study is the first retrospective, long-term analysis of metformin as adjuvant therapy to insulin in patients with T1DM.

A meta-analysis compared the renal side effects of SGLT2 inhibitors in patients with type 2 diabetes.

Under what circumstances may fructosamine levels be useful in monitoring glucose control?

The health effects of sedentary behavior, such as screen time, include adiposity & T2DM risk in adults. How does screen time affect children?

A study compared mortality and major adverse cardiovascular events in patients with type 2 diabetes prescribed metformin or insulin.

Could insulin could be dosed off of values from a continuous glucose monitor? Anne Peters, MD, and team sought to find out.

Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.